Reference

AMET works diligently to keep the following information updated with the most current medical aesthetic news.  This information has been supplied by numerous sources. AMET is not affiliated with any such sources, and the information provided does not reflect the views of AMET.  The function of this page is to simply provide information, and AMET does not accept responsibility or liability for any views/claims/rumors/errors that appears herein.  

10/24/2011
Topical Neurotoxin Erases Crow's Feet
The most recent phase 2 studies on a topically delivered botulinum toxin type A lend clinical support to an investigational product that physicians might use one day to essentially wipe away crow's feet wrinkles around the eyes, according to a consultant for the developer.
Topical Neurotoxin Erases Crow's Feet

Topical Neurotoxin Erases Crow's Feet


By Rod Franklin

The most recent phase 2 studies on a topically delivered botulinum toxin type A lend clinical support to an investigational product that physicians might use one day to essentially wipe away crow's feet wrinkles around the eyes, according to a consultant for the developer.

Addressing members at the ASPS annual meeting, Michael Kane, MD, a plastic surgeon in private practice in New York City, emphasized the exacting efficacy standards that were observed in two randomized trials that tested a gel known as RT001, which employs a novel macromolecule delivery system to relax muscles in the sensitive periorbital area.

"We're actually getting a very large payload to go through cell membranes and skin cells, allowing for penetration down to the muscle," the New York surgeon reports. "Throughout phase 2 we've had 11 clinical trials, and over 550 patients have been treated with the drug. We've had no treatment-related serious adverse events, and we've had a 115-day duration of effect."

RT001, under development by California-based Revance Therapeutics, was well tolerated in a double-blind placebo-controlled study of 90 patients and in a study of 180 patients that compared the compound's individual components. The product is now scheduled for its end-of-phase 2 review.

In the botulinum toxin type A gel is a peptide carrier that penetrates skin to relax the orbicularis oculi muscle. Although it can be topically applied, RT001 won't be sold over the counter; it requires the assistance of a physician. If approved, it will be marketed as a painless alternative for people who would otherwise be treated with injectable botulinum toxin A (Botox).


http://www.plasticsurgerypractice.com/eReport/2011...

back to reference main